|
Fibrosis, Liver
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
In fatty livers, DNase II activity is suppressed in contrast to simple inactivation of Bcl-xL or Mcl-1, and both apoptotic and non-apoptotic hepatocyte death can develop, leading to the progression of liver fibrosis.
|
29855540 |
2019 |
|
Rheumatoid Arthritis
|
0.230 |
AlteredExpression
|
disease |
BEFREE |
Since the three SNPs in the promoter region of the DNase II gene could affect in vivo DNase II activity through reduction of the promoter activity, it is feasible to identify these SNPs susceptible to RA.
|
23019102 |
2012 |
|
Hypothyroidism
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Based on these results, we can conclude that in the liver of hypothyroid rats the transcriptional activation by T2 of DNL genes could depend, at least in part, on SREBP-1- and ChREBP-dependent mechanisms.© 2019 IUBMB Life, 2019.
|
30707786 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.330 |
Biomarker
|
disease |
BEFREE |
Most Dnase1 and Dnase2 family members are poorly characterized, yet their elimination can lead to a wide range of diseases, including lethal anemia, parakeratosis, cataracts and systemic lupus erythematosus.
|
28666955 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.330 |
Biomarker
|
disease |
BEFREE |
Genetic associations of DNase II with SLE and related phenotypes were examined in Korean patients with SLE.
|
15723160 |
2005 |
|
Lupus Erythematosus, Systemic
|
0.330 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Type I interferon-mediated autoinflammation due to DNase II deficiency.
|
29259162 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.330 |
Biomarker
|
disease |
BEFREE |
We describe a 17-year-old boy with DNase II deficiency, presenting a clinical picture with significant overlap with systemic lupus erythematosus.
|
31448075 |
2020 |
|
Fibrosis, Liver
|
0.320 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Type I interferon-mediated autoinflammation due to DNase II deficiency.
|
29259162 |
2017 |
|
Glomerulonephritis, Membranoproliferative
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Type I interferon-mediated autoinflammation due to DNase II deficiency.
|
29259162 |
2017 |
|
Autoinflammatory disorder
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Type I interferon-mediated autoinflammation due to DNase II deficiency.
|
29259162 |
2017 |
|
Rheumatoid Arthritis
|
0.230 |
Biomarker
|
disease |
MGD |
|
|
|
|
Rheumatoid Arthritis
|
0.230 |
Biomarker
|
disease |
BEFREE |
The association of DNASE2 -1066 GG homozygosity with RA was limited to rheumatoid factor-positive disease, but was not influenced by the presence of anti-cyclic citrullinated peptide or antinuclear antibodies.
|
18812394 |
2009 |
|
Arthritis, Adjuvant-Induced
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.
|
20974942 |
2010 |
|
Splenomegaly
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.
|
20974942 |
2010 |
|
Arthritis, Collagen-Induced
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.
|
20974942 |
2010 |
|
Arthritis, Experimental
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation.
|
20974942 |
2010 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
The association of SNPs in the 5'-regulatory region of the DNA degrading enzyme DNASE2 with RA implies a role for this enzyme in the pathogenesis of this autoimmune disease.
|
18812394 |
2009 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
In addition, if nucleases, such as DNase II or DNase III (Trex1), fail to clear self-DNA, accumulated DNA gains access to intracellular compartments where it drives inflammatory responses leading to autoimmune disease.
|
23417527 |
2013 |
|
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
To continue our previous investigations, we have extensively investigated the function of the 61, 41, and 35 non-synonymous single nucleotide polymorphisms (SNPs) in the human genes encoding DNASE1, DNASE1L3, and DNASE2, respectively, potentially relevant to autoimmune diseases.
|
27116004 |
2016 |
|
Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
DNase II(-/-) embryos suffer from lethal anemia due to IFN-beta produced in the macrophages carrying undigested DNA.
|
20706988 |
2010 |
|
Anemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Most Dnase1 and Dnase2 family members are poorly characterized, yet their elimination can lead to a wide range of diseases, including lethal anemia, parakeratosis, cataracts and systemic lupus erythematosus.
|
28666955 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The inhibitory action on DNL exerted by T2 makes this compound a potential and attractive drug for the treatment of some metabolic diseases and cancer.
|
28362337 |
2017 |
|
Fatty Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Inhibition of DNL is a successful approach to reverse hepatic steatosis, as shown by different studies in mice and humans.
|
30630736 |
2019 |
|
Fatty Liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here, we give an overview of the mechanisms of THs action on liver fatty acid metabolism, focusing on the different effects exerted by T2 and T3 on the regulation of the DNL.
|
28362337 |
2017 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
SNPs in DNL genes may serve as independent prognostic markers for HCC patients after surgery.
|
25826294 |
2015 |